Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GPCR 
Structure Therapeutics Inc. American Depositary Shares (GPCR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: GPCR (2-star) is a SELL. SELL since 1 days. Simulated Profits (19.52%). Updated daily EoD!
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $73.21
1 Year Target Price $73.21
| 8 | Strong Buy |
| 6 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 71.87% | Avg. Invested days 33 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.52B USD | Price to earnings Ratio - | 1Y Target Price 73.21 |
Price to earnings Ratio - | 1Y Target Price 73.21 | ||
Volume (30-day avg) 14 | Beta -1.76 | 52 Weeks Range 13.22 - 42.57 | Updated Date 10/25/2025 |
52 Weeks Range 13.22 - 42.57 | Updated Date 10/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.15 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -15.57% | Return on Equity (TTM) -21.14% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 754437145 | Price to Sales(TTM) - |
Enterprise Value 754437145 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -13.46 | Shares Outstanding 57597939 | Shares Floating 133598995 |
Shares Outstanding 57597939 | Shares Floating 133598995 | ||
Percent Insiders 3.02 | Percent Institutions 97.54 |
Upturn AI SWOT
Structure Therapeutics Inc. American Depositary Shares
Company Overview
History and Background
Structure Therapeutics, Inc. is a clinical-stage global biopharmaceutical company focused on discovering and developing novel oral therapeutics for chronic diseases with significant unmet needs. Founded in 2016, it has rapidly advanced its pipeline, leveraging its structure-based drug discovery platform.
Core Business Areas
- GPCR Targeted Therapeutics: Focuses on developing small molecule drugs that target G protein-coupled receptors (GPCRs), a large family of cell surface receptors involved in a wide range of physiological processes.
- Metabolic Disorders: Developing treatments for metabolic disorders, with a lead program targeting obesity and related conditions.
- Pulmonary Fibrosis: Exploiting GPCR targets to create novel therapeutics for Pulmonary Fibrosis.
Leadership and Structure
Raymond Stevens (Founder and CEO). The organizational structure follows typical biotech company lines with research and development, clinical development, and business operations departments.
Top Products and Market Share
Key Offerings
- GSBR-1290: An oral, small molecule GLP-1 receptor agonist in Phase 2 clinical trials for obesity and type 2 diabetes. Competing GLP-1 agonists include Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro. Market share is currently 0% as it is in clinical development, but projected peak sales are estimated to be significant based on current market leaders.
- ANPA-0073: An oral, small molecule, Phase 1 APJR agonist targeting Idiopathic Pulmonary Fibrosis. Market share is 0% as it is in early clinical development.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and innovative, with a focus on developing new treatments for a wide range of diseases. The obesity and diabetes market is particularly large and growing rapidly due to increasing prevalence of these conditions. Pulmonary Fibrosis has a much smaller market, but has huge unmet needs.
Positioning
Structure Therapeutics is positioned as an innovator in the oral GLP-1 receptor agonist space, offering a potentially more convenient and accessible treatment option compared to injectable drugs. Their expertise in structure-based drug design gives them a competitive advantage in discovering novel GPCR-targeted therapies.
Total Addressable Market (TAM)
The TAM for obesity and type 2 diabetes therapeutics is estimated to be over $50 billion annually, with significant growth projected. Structure Therapeutics is aiming to capture a substantial portion of this market with its oral GLP-1 agonist. The Pulmonary Fibrosis TAM is considerably smaller but is estimated to be > $5 Billion with significant unmet needs.
Upturn SWOT Analysis
Strengths
- Novel oral GLP-1 agonist in clinical development
- Strong structure-based drug discovery platform
- Experienced management team
- Targeting large and growing markets
Weaknesses
- Early-stage clinical development (high risk)
- Reliance on clinical trial results
- Intense competition from established pharmaceutical companies
- Requires significant capital to fund clinical trials and drug development
Opportunities
- Positive clinical trial results could drive significant stock appreciation
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other GLP-1 agonists
- Patent challenges
Competitors and Market Share
Key Competitors
- Novo Nordisk (NVO)
- Eli Lilly (LLY)
- Amgen (AMGN)
- Viking Therapeutics (VKTX)
Competitive Landscape
Structure Therapeutics is competing in a crowded market with established pharmaceutical giants. Its competitive advantage lies in its oral GLP-1 agonist and structure-based drug discovery platform. Its small size relative to these established companies is a disadvantage.
Growth Trajectory and Initiatives
Historical Growth: Since its founding in 2016, growth has been focused on expanding its pipeline and advancing its lead drug candidate through clinical trials.
Future Projections: Future growth is dependent on successful clinical trial outcomes and potential commercialization of its drug candidates. Analyst estimates vary widely depending on the perceived probability of success.
Recent Initiatives: Advancing GSBR-1290 into Phase 2 clinical trials, expanding the pipeline with new GPCR targets, and strengthening its intellectual property portfolio.
Summary
Structure Therapeutics is a promising clinical-stage biopharmaceutical company with a novel oral GLP-1 agonist in development. Success hinges on positive clinical trial results and navigating the competitive landscape. The strong cash position provides runway, but clinical trial risks remain. The company must compete with well-established companies with much bigger budgets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Structure Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual due diligence and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Structure Therapeutics Inc. American Depositary Shares
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2023-02-03 | CEO & Director Dr. Raymond C. Stevens Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 199 | Website https://structuretx.com |
Full time employees 199 | Website https://structuretx.com | ||
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in preclinical trial to treat obesity; ANPA-0073, an oral small molecule agonist targeting the apelin, which is phase 2 ready for selective weight loss or muscle-sparing weight loss; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.